Acta Biomater. 2025 Jul 3:S1742-7061(25)00503-3. doi: 10.1016/j.actbio.2025.07.010. Online ahead of print.
ABSTRACT
Metabolic dysfunction-associated steatohepatitis (MASH), as a chronic inflammatory liver disease, presents a significant challenge for effective drug delivery due to excess extracellular matrix (ECM). Here, a reactive oxygen species (ROS)/ultrasound (US) dual-responsive nanodrug loaded with resmetirom and perfluorohexane (PFH), termed RP-LipoTK, was developed for treatment of MASH via scavenging ROS and US-promoted deep drug penetration. The ROS-responsive component of RP-LipoTK achieved selective PEG shedding under ROS-enriched environments of MASH liver. This process facilitated the enhanced accumulation of nanodrug within fibrotic liver tissues. Meanwhile, the PEG shedding synergistically scavenged ROS, thereby mitigating oxidative stress in MASH livers. Subsequently, the cavitation effect of PFH under US exposure elicited a rapid release of resmetirom and promoted its deep penetration into the dense ECM of fibrotic MASH liver tissues. Consequently, RP-LipoTK + US effectively delivered resmetirom into MASH hepatocytes and activated the thyroid hormone receptor β (THR-β) signaling pathways, which distinctly alleviated hepatic steatosis, mitigated liver inflammation and improved lipid metabolism in a MASH mouse model. Collectively, the combination of RP-LipoTK and US represented a promising strategy for the effective management of MASH. STATEMENT OF SIGNIFICANCE: Resmetirom, a first-line drug approved by FDA for the treatment of MASH, has demonstrated promising therapeutic potential in disease management. However, the excessive deposition of extracellular matrix (ECM) in fibrotic MASH liver that restricts drug penetration, as well as the limited oral bioavailability of resmetirom, lead to unsatisfactory treatment efficacy. To overcome these challenges, intravenous administration of resmetirom coupled with an optimized drug delivery system was developed for efficient MASH treatment. Herein, we designed a reactive oxygen species (ROS)/ultrasound (US) dual-responsive nanodrug co-loaded with resmetirom and perfluorohexane (PFH). The nanodrug combines ROS scavenging and US-promoted drug penetration to overcome ECM barriers, resulting in efficient drug delivery in MASH liver. Collectively, the nanodrug achieves significant reduction in inflammation, lipid accumulation, and fibrosis in a MASH mouse model, providing a promising strategy for MASH management.
PMID:40617493 | DOI:10.1016/j.actbio.2025.07.010